Terms of Issue under the EMTN 2020 NOTE PROGRAMME

MedTech VC (EMTN20/21)

Dated July 21st, 2022

PRAETORIAN ASSETS S.à r.l.

Société à Responsabilité Limitée

17, Rue de Flaxweiler, L-6776 Grevenmacher Grand Duchy of Luxembourg

RCSL B240638

TERMS OF ISSUE

MedTech VC

issued by

PRAETORIAN ASSETS S.à r.l.

(a limited liability company incorporated and organised as a securitisation company under the laws of Luxembourg)

pursuant to the

EUR 500.000.000,00

EMTN 2020 NOTE PROGRAMME

Dated September 10th, 2020

of

PRAETORIAN ASSETS S.à r.l.

Legal Entitiy Identifier:

22210049GKPFLCLQSW74

Issue Price: 100 per cent.

Issue Date: November 03rd, 2021

(the "Notes")

The Notes issued by the Issuer will be subject to the Terms and Conditions of the Programme and also to the following Terms of Issue (the "Terms of Issue") in relation to the Notes.

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions set forth in the Terms and Conditions dated September 10th, 2020.

For the purpose of these Terms of Issue, references to Terms and Conditions of the Programme shall be read and construed as references to Terms of Issue in respect of the Notes. This document constitutes the applicable Terms of Issue of the Notes and must be read in conjunction with the Terms and Conditions of the Programme. Full information on the Issuer and the offer of the Notes is only available on the basis of the combination of these applicable Terms of Issue and the and Conditions of the Programme.

This Series of Notes will reflect the performance of the underlying assets (the "**Underlying Assets**") as described herein. The Series of Notes are not principal protected and the Redemption Price depends on the value of the Underlying Assets on the date of Redemption by the Noteholder(s).

PROHIBITION OF SALES TO RETAIL INVESTORS IN THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM

The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA") or in the United Kingdom. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended) (the "PRIIPs Regulation") for offering or selling the Securities or otherwise making them available to retail investors in the EEA or in the United Kingdom has been prepared and therefore offering or selling the Securities or otherwise making them available to any retail investor in the EEA or in the United Kingdom may be unlawful under the PRIIPs Regulation. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended) ("MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC.

MIFID II PRODUCT GOVERNANCE / ELIGIBLE COUNTERPARTIES AND PROFESSIONAL CLIENTS ONLY TARGET MARKET

Solely for the purposes of the Issuer product approval process, the target market assessment in respect of the Notes has led to the conclusion that (i) the target market for the Notes is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, "MiFID II"); and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "Distributor") should take into consideration the Issuer's target market assessment; however, a Distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Notes by either adopting or refining the Issuer's target market assessment or determining appropriate distribution channels.

Contractual Terms

SERIES (NOTE) DETAILS

ISIN Code: CH1108674149

Valoren: 110867414

Compartment: EMTN20/21

Eurosystem eligibility of Notes No

Series Name: MedTech VC

Currency: USD

Aggregate Nominal Amount

of Notes:

Up to USD 10.000.000,00 (with re-opening clause)

Issue Price: 100%

Denomination: USD 10.000,00

Issue Date: November 03rd, 2021

Initial Subscription Period: Until November 02nd, 2021

Maturity Date: November 05th, 2026 (with re-opening clause)

The Issuer reserves the right to extend the maturity date by one year at a time. However, the maximum extension of

the maturity date is limited to 2 years.

Redemption/Payment Basis: Value of outstanding nominal amount

Early Redemption: The Issuer reserves the right to redeem part or all of the

Notes at any time, at its own discretion and subject to a 10-

day notice period.

Early Redemption Amount: Value of outstanding nominal amount

Administration Fees: 0,50 per cent per annum with a minimum of EUR 35.000,00

per annum

Transaction Fee: Up to 1,00 per cent (based on the price of the notes)

Subscription Fee: Up to 1,00 per cent (in addition to the issue price of the notes)

Other Costs: As at per invoice

INTEREST (IF ANY) PAYABLE

Fixed Rate Note Provisions: N/A

Floating Rate Note Provisions: Based on the value of the underlying asset and Fees on the

Interest Commencement Date (including) until the next

Interest Commencement Date (excluding).

Zero Coupon Note Provisions: N/A

Business Day Convention: a day on which the Systems are open for the settlement of

payments in the respective currency. Unadjusted, modified

following business day convention.

Day Count Fraction: 30/360

Interest Commencement Date(s): November 03rd, 2021

Interest Payment Date(s): November 05th, 2026 (at Maturity)

Calculation Basis Aggregate outstanding principal amount of the notes

UNDERLYING ASSETS

Underlying Assets: Share Class D of the Subfund "MedTech Venture Capital" of

the PA S.C.S. SICAV-RAIF with ISIN LU2377360529.

Use of proceeds: The net proceeds from each issue of Notes will be used to

purchase or otherwise acquire Underlying Assets, to pay for or enter into any ancillary transaction in connection with the issue of such Notes or acquisition of such Underlying Assets and to pay general expenses in connection with the administration of the Issuer, the issue of the Notes or

acquisition of the Underlying Assets.

GENERAL PROVISIONS APPLICABLE TO THE NOTES

Legal type of Notes: Bearer Global Note

Governing Law Luxembourg Law

Business Day Convention Modified Following Business Day Convention

Clearing System SIX SIS AG

Status of the Notes Unsecured

Agents

Administration and Calculation Agent MTCM Securities SA

Custodian N/A

Paying Agent ISP Securities AG

Arranger MTCM Investments AG

Publications Applicable

Notification to Clearing System Applicable

Resolutions of Noteholders Simple Majority (50%)

Language of Terms and Conditions English only

Website <u>www.MTCM.lu</u>

LISTING

Listing and admission to trading No

Expected date of admission N/A

RESPONSIBILITY

The Issuer accepts responsibility for the information contained in this document and declares that, having taken all reasonable care to ensure that such is the case, the information contained in this document is, to the best of its knowledge, in accordance with the facts and contains no omission likely to affect its import.

Signed on behalf of the Issuer acting in respect of and on account of the Compartment:

By:

Jose Benitez

DocuSigned by: